Panacea Venture is a healthcare venture fund with global vision and reach dedicated to transforming lives through promising innovation.

Panacea Venture

Panacea Venture is a life sciences venture capital firm with global vision and presence across three continents. The firm was founded in 2017 and is currently managing four funds investing in early-stage companies through public investments. Panacea incubates early-stage companies with breakthrough technologies and discoveries that can potentially address unmet medical needs to enhance quality of life on a global scale. The investment team has more than 100 years of combined investing experience and, along with venture partners and advisors, provides broad coverage across emerging and established biotech, diagnostic and medtech sectors. In addition, Panacea’s highly experienced team has a strong track record navigating portfolio companies to success.  

New Amsterdam Pharma

Johnson & Johnson Innovation – JLABS recognizes that unlocking investment opportunities is every start-up's biggest challenge and continue facilitating connections between regional and global investment funds and Singapore’s life-science ecosystem.
 
On August 29, JLABS will introduce Panacea Venture at the stunning co11ab Novena in Singapore! Our Founder and Managing Partner, James Huang brings an impressive background as an investor, entrepreneur, and corporate experience at companies previously acquired by big pharma. There will also be a star panel discussion featuring distinguished industry experts alongside James, including Yue (Shelby) Zhang and David M Epstein being moderated by JLABS Ronne Yeo

#biotech #investing #JLABS #lifesciences

We are pleased to announce that the Investigational New Drug (“IND”) application of Cyclosporine A (“CsA”) Ophthalmic Gel for the treatment of moderate to severe dry eye disease (“DED”) has been approved by the National Medical Products Administration (the “NMPA”) of China.  This Phase III clinical trial has been designed to closely follow the requirements outlined by the Center for Drug Evaluation (the “CDE”) in its Technical Guidelines on Clinical Trials for Therapeutic Drugs for Dry Eyes issued in September 2023.
 
We are also pleased to announce that on 5 August 2024, the last patient last visit was completed for the two-year Phase III clinical trial (“China CHAMP”) of our core product NVK002, a treatment for myopia progression control. 

For more information, please visit:
https://lnkd.in/d5M8H4hA

#zhaoke #ophthalmology #healthcare #eyecare #pharmaceutical #biotech #dryeye #myopia

Congratulations to Human Longevity for completing Series B financing further supporting their efforts of developing innovative solutions to help people live longer, healthier lives!

Thank you Human Longevity, Inc. for inviting me to give a keynote on the latest advancements in #longevitymedicine. Tailoring the interventions to an individual is crucial for maximizing their effectiveness. Honored to talk more about it on July 10th.
#longevityphyscian #healthylongevity

link: https://lnkd.in/d6gqpSgG

The FDA’s official press release regarding the START Pilot Program includes Myrtelle as 1 of 4 CBER participants. Read the full article below! #fda #STARTProgram #myrtelle
https://bit.ly/3zoOecV

PANA

COM:PANACEAVENTURE

Panacea Venture